Cargando…

Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies

The calcium (Ca(2+))-dependent membrane-binding Annexin A6 (AnxA6), is a multifunctional, predominantly intracellular scaffolding protein, now known to play relevant roles in different cancer types through diverse, often cell-type-specific mechanisms. AnxA6 is differentially expressed in various sta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Korolkova, Olga Y., Widatalla, Sarrah E., Williams, Stephen D., Whalen, Diva S., Beasley, Heather K., Ochieng, Josiah, Grewal, Thomas, Sakwe, Amos M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465958/ https://www.ncbi.nlm.nih.gov/pubmed/32784650 http://dx.doi.org/10.3390/cells9081855

Ejemplares similares

Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors
por: Widatalla, Sarrah E, et al.
Publicado: (2019)

Identification of MAGEC2/CT10 as a High Calcium-Inducible Gene in Triple-Negative Breast Cancer
por: Beasley, Heather K., et al.
Publicado: (2022)

Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility
por: Whalen, Diva S., et al.
Publicado: (2019)

Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets
por: Korolkova, Olga Y., et al.
Publicado: (2020)

Association of calcium sensing receptor polymorphisms at rs1801725 with circulating calcium in breast cancer patients
por: Wang, Li, et al.
Publicado: (2017)

Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists
por: Williams, Stephen D., et al.
Publicado: (2022)

Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors
por: Koumangoye, Rainelli B, et al.
Publicado: (2013)

Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes
por: Ochieng, Josiah, et al.
Publicado: (2018)

Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells
por: Williams, Stephen D., et al.
Publicado: (2022)

Fetuin-A Promotes 3-Dimensional Growth in LNCaP Prostate Cancer Cells by Sequestering Extracellular Vesicles to Their Surfaces to Act as Signaling Platforms
por: Ochieng, Josiah, et al.
Publicado: (2022)

The α2-HeremansSchmid glycoprotein (AHSG) promotes growth in head and neck squamous cell carcinoma (HNSCC)
por: Thompson, Pamela D, et al.
Publicado: (2013)

Detachment of Breast Tumor Cells Induces Rapid Secretion of Exosomes Which Subsequently Mediate Cellular Adhesion and Spreading
por: Koumangoye, Rainelli B., et al.
Publicado: (2011)

Shotgun proteomic analysis of human head and neck squamous cell carcinoma cell line SQ20B with diminished AHSG expression
por: Iyamu, Georgina, et al.
Publicado: (2014)

Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer
por: Li, Ting, et al.
Publicado: (2021)

Fetuin‐A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high‐grade astrocytomas
por: Nangami, Gladys N., et al.
Publicado: (2016)

The Calcium-Sensing Receptor (CaSR) Variants at rs1801725 Increase the Risk of Developing Secondary Malignant Cancers
por: Beasley, Heather K, et al.
Publicado: (2021)

The rapid endocytic uptake of fetuin‐A by adherent tumor cells is mediated by Toll‐like receptor 4 (TLR4)
por: Thomas, Portia L., et al.
Publicado: (2020)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Analysis of CK5/6 and EGFR and Its Effect on Prognosis of Triple Negative Breast Cancer
por: Wang, Zhen, et al.
Publicado: (2021)

A Cell-Based Systematic Review on the Role of Annexin A1 in Triple-Negative Breast Cancers
por: Pearanpan, Lishantini, et al.
Publicado: (2022)

Calcium-Sensing Receptor Polymorphisms at rs1801725 Are Associated with Increased Risk of Secondary Malignancies
por: Actkins, Ky’Era V., et al.
Publicado: (2021)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR expression is associated with cytoplasmic staining of CXCR4 and predicts poor prognosis in triple-negative breast carcinomas
por: Li, Rong-Hui, et al.
Publicado: (2017)

Inhibition of triple-negative and Herceptin-resistant breast cancer cell proliferation and migration by Annexin A2 antibodies
por: Chaudhary, P, et al.
Publicado: (2014)

Inhibition of Triple-Negative Breast Cancer Cell Aggressiveness by Cathepsin D Blockage: Role of Annexin A1
por: Zóia, Mariana Alves Pereira, et al.
Publicado: (2019)

Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

Annexins in Adipose Tissue: Novel Players in Obesity
por: Grewal, Thomas, et al.
Publicado: (2019)

Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Triple-negative breast cancer: current treatment strategies and factors of negative prognosis
por: Baranova, Anna, et al.
Publicado: (2022)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Correction to: Serum exosomal-annexin A2 is associated with African-American triple-negative breast cancer and promotes angiogenesis
por: Chaudhary, Pankaj, et al.
Publicado: (2020)

Annexins—Coordinators of Cholesterol Homeostasis in Endocytic Pathways
por: Rentero, Carles, et al.
Publicado: (2018)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Triple-Negative Breast Cancer with High Levels of Annexin A1 Expression Is Associated with Mast Cell Infiltration, Inflammation, and Angiogenesis
por: Okano, Maiko, et al.
Publicado: (2019)

Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer
por: Powrózek, Tomasz, et al.
Publicado: (2022)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
por: Inoue, Satoshi, et al.
Publicado: (2012)

Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer
por: Sood, Neelam, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_43l2pgc7m23q3f4fsdo4rpnu7l